Background: The use of extracorporeal membrane oxygenation (ECMO) during cardiopulmonary resuscitation (ECPR) is increasing. Prehospital ECPR (PH-ECPR) for out-of-hospital cardiac arrest (OHCA) may improve both equity of access and outcomes but its cost effectiveness has yet to be determined.
Methods: Cost analyses of PH-ECPR was performed utilizing current PH-ECPR trial, NSW Ambulance Cardiac Arrest Registry (CAR), geospatial modelling and in-hospital costings data. Markov modelling was completed to combine the PH-ECPR cost analysis with reported patient outcomes across multiple ECPR strategies. Bridging formulae from ECPR survivor cerebral performance category (CPC) scores were used to estimate cost per quality adjusted life years (QALY) and Incremental Cost Effectiveness Ratios (ICERs). Probabilistic Sensitivity Analysis was completed to assess the probability of cost effectiveness for base case and PH-ECPR strategy variations.
Results: Assuming a base case of 100 patients per year, with a 25% team allocation to ECPR, the average pre-hospital ECPR cost per patient was $12,741 and total of $88,656 AUD equating to approximately $44,000 per QALY. Addition of a conservative 10% kidney organ donation rate reduces the cost per QALY to $22,000. Patient survival rate, the proportion of time the pre-hospital ECPR team are allocated to ECPR and organ donation significantly impact PH-ECPR cost effectiveness.
Conclusion: Initial cost analysis and modelling indicate PH-ECPR service strategies are likely to be cost effective and comparable to other medical interventions. Survival rate and service integration into non ECPR clinical tasks are key aspects contributing to cost effectiveness.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.resuscitation.2024.110488 | DOI Listing |
JACS Au
January 2025
Department of Chemistry, University of Missouri, 601 South College Avenue, Columbia, Missouri 65211, United States.
Our newly developed AshPhos ligand represents a significant advancement in Buchwald-Hartwig aminations, overcoming many limitations of existing ligands. Created from affordable and accessible materials, AshPhos enhances catalytic performance, especially for extremely difficult substrates, by emphasizing the principles of ligand chelation and cooperativity. Its successful synthesis and application in catalytic aminations underscore its potential for use in the sustainable synthesis of compounds important to medicinal chemistry, materials, and energy.
View Article and Find Full Text PDFOnt Health Technol Assess Ser
January 2025
Background: Chronic neuropathic pain is a major health problem that adversely affects people's physical and mental well-being, as well as their quality of life. Percutaneous peripheral nerve stimulation (PNS) may offer a minimally invasive option earlier in the treatment continuum for adults with chronic neuropathic pain that is refractory to conventional medical management. We conducted a health technology assessment of PNS for adults with chronic neuropathic pain, which included an evaluation of effectiveness, safety, cost-effectiveness, the budget impact of publicly funding PNS, and patient preferences and values.
View Article and Find Full Text PDFIndian J Orthop
February 2025
Department of Orthopaedics, JSS Medical College, Mysore, 570004 India.
Background: Rickets is a common metabolic bone disease in children, primarily caused by vitamin D deficiency. This study aimed to compare the efficacy of oral weekly vitamin D supplementation and injectable stoss therapy in treating nutritional rickets in Indian children.
Methods: This prospective, randomized, controlled trial was conducted over 18 months at a tertiary care center.
Indian J Orthop
February 2025
Department of Orthopaedics, All India Institute of Medical Sciences (AIIMS), Phulwari Sharif, Aurangabad Road, Patna, Bihar 801507 India.
Background: The implementation of the standard Ponseti technique (SPT) in management of idiopathic clubfoot can be challenging due to the need for frequent travelling and long duration to achieve correction. The one week accelerated Ponseti technique (OWAPT) reduces the duration of correction to seven days and has been reported to be effective and safe. However, children still need to travel for change of cast.
View Article and Find Full Text PDFFuture Cardiol
January 2025
Duke Clinical Research Institute, Duke University, Durham, NC, USA.
Background: ALERTS was a pivotal randomized clinical trial (RCT) evaluating an intracardiac monitor with real-time alerting in high-risk acute coronary syndrome patients. The cost-effectiveness however is unknown.
Method: A decision model estimated health effects and costs of implanting a Guardian device in a target patient population, compared to current standard-of-care (SOC).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!